US EditionAdvancing Influenza Vaccine Development: Sino Biological Launches Antigens for the 2026-2027 Northern Hemisphere Influenza Vaccine Strains
Sino Biological offers recombinant antigens aligned with WHO's updated 2026–2027 flu vaccine strains to support global research amid rising H3N2 and B/Victoria activity, WHO said.
- From Houston, Sino Biological announced on March 3, 2026, the launch of a recombinant antigen panel for 2026–2027 influenza vaccine strains.
- The World Health Organization announced recommendations for the 2026–2027 vaccine, prompted by B/Victoria activity rising from 6% to over 20%, and the dominance of H3N2 subclade K.
- Now available: recombinant HA, NA and NP aligned to A/Darwin/1454/2025, with A/Missouri/11/2025 H1N1 HA trimer validated by SEC‑MALS and ELISA.
- Serving researchers in more than 90 countries, Sino Biological aims to accelerate influenza vaccine research, said Dr. Rob Burgess, 'Our mission is to provide the scientific community with the highest quality tools as rapidly as possible when infectious disease evolution threatens global health preparedness.'
- Sino Biological noted that forward-looking statements are subject to uncertainty and management's expectations may change, with no obligation to update, per the Private Securities Litigation Reform Act.
35 Articles
35 Articles
Waterloo Cedar Falls Courier
Advancing Influenza Vaccine Development: Sino Biological Launches Antigens for the 2026-2027 Northern Hemisphere Influenza Vaccine Strains
HOUSTON, March 3, 2026 /PRNewswire/ -- The World Health Organization (WHO) has announced its recommendations for the 2026–2027 Northern Hemisphere influenza vaccine composition, highlighting the continued spread of A(H3N2) subclade K and emerging B/Victoria lineage strains. In rapid response, Sino…
Sino Biological Launches Antigens for the 2026-2027 Northern Hemisphere Influenza Vaccine Strains
HOUSTON, March 3, 2026 /PRNewswire/ — The World Health Organization (WHO) has announced its recommendations for the 2026–2027 Northern Hemisphere influenza vaccine composition, highlighting the continued spread of A(H3N2) subclade K and emerging B/Victoria lineage strains. In rapid response, Sino Biological, Inc. (Shenzhen Stock Exchange: 301047.SZ), a global leader in recombinant technology, has launched the 2026-2027 Northern Hemisphere influe…
Coverage Details
Bias Distribution
- 86% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
